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Abstract
Purpose Most US inflammatory bowel disease (IBD)
epidemiology studies conducted to date have sampled
small, geographically restricted populations and have not
examined time trends. The aim of our study was to deter-
mine the prevalence of Crohn’s disease (CD) and ulcera-
tive colitis (UC) in a commercially insured US population
and compare prevalences across sociodemographic char-
acteristics and time.
Methods Using claims data from approximately 12 mil-
lion Americans, we performed three consecutive 2-year
cross-sectional studies. Cases of CD and UC were identi-
fied using a previously described algorithm. Prevalence
was estimated by dividing cases by individuals in the
source population. Logistic regression was used to compare
prevalences by region, age, and sex.
Results In 2009, the prevalences of CD and UC in chil-
dren were 58 [95 % confidence interval (CI) 55–60] and 34
(95 % CI 32–36), respectively. In adults, the respective
prevalences were 241 (95 % CI 238–245) and 263 (95 %
CI 260–266). Data analysis revealed that IBD prevalences
have slightly increased over time. Based on census data, an
estimated 1,171,000 Americans have IBD (565,000 CD
and 593,000 UC).
Conclusions Analysis of the epidemiological data revealed
an increasing burden of IBD in recent years, which may be
used to inform policy.
Keywords Crohn’s disease  Ulcerative colitis 
Prevalence  Epidemiology
Introduction
Crohn’s disease (CD) and ulcerative colitis (UC), collec-
tively referred to as the inflammatory bowel diseases
(IBDs), are characterized by chronic inflammation of the
gastrointestinal tract. The cause(s) of these diseases is
unknown; however, genetics/family history, and environ-
mental factors appear to influence disease risk. Epidemio-
logical studies of IBD in the USA are necessary to quantify
the public health burden of disease and inform policy
regarding the allocation of resources and provision of
health services for affected individuals. Because IBD is not
a reportable condition in the USA and comprehensive,
nationwide registries for IBD surveillance have not been
established, published studies on the epidemiology of IBD
in the USA [1–6] are limited and primarily include studies
which have sampled small, geographically restricted pop-
ulations. Furthermore, no studies of IBD prevalence have
been published using data from the last 5 years and,
therefore, current time trends remain unknown.
The aims of this study were (1) to estimate the current
prevalence of IBD in the USA as of 2009 using a large,
regionally diverse population of commercially insured
individuals, and (2) to examine recent trends in disease
prevalence. A further aim was to characterize differences
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in disease epidemiology by geographic region, age, and
sex.
Materials and Methods
Study Design and Data Source
Using the inpatient, outpatient, and pharmaceutical insur-
ance claims data sets contained within the PharMetrics
Choice Patient-Centric Database (IMS Health, Watertown,
MA), we performed three consecutive cross-sectional
studies for the following 2-year time periods: 1 January
2004–31 December 2005, 1 January 2006–31 December
2007, and 1 January 2008–31 December 2009. This data-
base pools together claims data from 20 to 25 commercial
health plans covering all four US census regions. The
majority of patients in the database have both medical and
pharmacy benefits. Mean health plan enrolment is 6.4
[interquartile range (IQR) 5.3–7.2] years for the 2004–2005
cohort, 5.8 (IQR 4.3–7.1) years for the 2006–2007 cohort,
and 4.6 (IQR 3.2–6.4) years for the 2008–2009 cohort.
Prior studies have reported PharMetrics to be representa-
tive of the national commercially insured population on a
variety of demographic measures [7].
Source Populations
All patients in the database with continuous health plan
enrollment for at least one of the above 2-year time periods
comprised the source population for this study. Individuals
turning 65 years of age or older (year of period end - year
of birth) during each 2-year period were removed from the
source population to avoid the possibility of missing data
due to Medicare dual-enrollment. The following demo-
graphic elements were available for all members of the
source population: year of birth, gender, and US census
region (Northeast, South, Midwest, and West).
Case Identification
The case definition used to identify prevalent cases of IBD
was adapted from a previously validated University of
Manitoba IBD Epidemiology Database definition [8] and
has been used in prior epidemiological studies of IBD [3,
9–12]. For each 2-year period, cases were identified as
individuals with at least 3 healthcare contacts, on different
days, associated with an International Classification of
Diseases 9th revision diagnosis code for CD (555.x) or UC
(556.x). Additionally, individuals with at least one claim
for CD or UC who also had at least one pharmacy claim for
an IBD-specific medication (mesalamine, olsalazine,
balsalazide, sulfasalazine, 6-mercaptopurine, azathioprine,
infliximab, adalimumab, certolizumab, natalizumab, metho-
trexate, and enteral-release budesonide) were also included
in our case definition. For those patients who had submitted
claims for both CD and UC, disease assignment was made
according to the majority of the last nine claims. If a dis-
tinction between CD and UC could not be made using these
criteria, cases were designated as IBD not otherwise speci-
fied (NOS). Each 2-year time period had a unique base
population depending on the number of patients who met the
above-mentioned eligibility criteria. Some individuals were
included in more than one time period if they met the
inclusion criteria over multiple years.
Statistical Analysis
Analyses were performed for each of the time periods:
2004–2005, 2006–2007, and 2008–2009. Prevalence
estimates were made for CD, UC, and total IBD (CD ?
UC ? IBD NOS) as of 31 December 2005, 31 December
2007, and 31 December 2009, respectively, by dividing the
number of identified cases by the corresponding number of
individuals in the source population. All estimates were
reported as cases per 100,000 persons, and also stratified by
age, gender, and US census region. Exact 95 % confidence
limits (95 % CI) were calculated using a variation on the
Wilson Score confidence interval method.
To determine the independent effects of age, gender, and
region on the prevalence of IBD in the final time period,
multivariable logistic regression was used to compare dif-
ferences in prevalence by age group, gender, and geo-
graphic region while controlling simultaneously for all
other data elements.
To estimate the projected number of people with IBD in
the US population as of 2009 and to determine adjusted
prevalence estimates, we multiplied the age, gender, and
region-specific prevalences obtained in our sample by the
corresponding US population according to census data.
Next, in order to facilitate our analysis of trends in the
prevalence of CD and UC across time periods, we stan-
dardized the estimates obtained in each period to reflect the
age, gender, and regional distribution of the US population
according to 2009 census data and conducted pairwise
comparisons (2006–2007 vs. 2004–2005; 2008–2009 vs.
2004–2005; 2008–2009 vs. 2006–2007) using t tests. We
recognize that t tests are based on the assumption that the
samples in the different time periods are independent and,
in fact, some individuals in this study contribute to more
than one time period. However, such repeated sampling
can be expected to increase the precision of the comparison
between time periods, making the tests conducted here
conservative.
All statistical analyses were performed using SAS ver.
9.1 or above (SAS Institute, Cary, NC).
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Ethical Considerations
As this study was an analysis of existing, de-identified data,
it is not considered to be human subject research.
Results
Source Population
The source population for each 2-year period comprised
5,621,520 individuals (29 % children \20 years of age) in
2004–2005, 8,139,941 individuals (28 % children) in
2006–2007, and 12,538,475 individuals (28 % children) in
2008–2009. Additional demographics for the source pop-
ulation are shown in Table 1.
IBD Prevalence in 2009
In this commercially insured population, the overall prev-
alences of CD and UC in the pediatric population were 58
and 34 per 100,000, respectively. In the adult population,
the overall prevalences of CD and UC were 241 and
263 per 100,000, respectively. Additional details on the
Table 1 Source population and demographics by time period in a commercially insured US population (2004–2009)
Demographic characteristic Time period
2004–2005, N (%) 2006–2007, N (%) 2008–2009, N (%)
Pediatric
Age group (years)
\5 218,748 (13) 305,439 (13) 461,434 (13)
5–9 403,811 (25) 567,674 (25) 886,112 (25)
10–14 477,600 (29) 660,328 (29) 1,019,459 (29)
15–19 526,478 (32) 748,376 (33) 1,123,040 (32)
Sex
Female 796,394 (49) 1,116,707 (49) 1,705,833 (49)
Male 830,209 (51) 1,164,984 (51) 1,784,000 (51)
Unspecifieda 34 126 212
Region
East 519,693 (32) 828,698 (36) 1,058,641 (30)
Midwest 676,579 (42) 935,961 (41) 1,049,693 (30)
South 117,605 (7) 137,539 (6) 802,302 (23)
West 312,760 (19) 379,619 (17) 579,409 (17)
Total 1,626,637 2,281,817 3,490,045
Adult
Age group (years)
20–29 607,718 (15) 863,664 (15) 1,351,846 (15)
30–39 757,898 (19) 1,088,520 (19) 1,682,856 (19)
40–49 1,119,239 (28) 1,576,415 (27) 2,333,139 (26)
50–59 1,120,411 (28) 1,674,602 (29) 2,600,671 (29)
60–64 389,617 (10) 654,923 (11) 1,079,918 (12)
Sex
Female 2,093,637 (52) 3,098,409 (53) 4,784,436 (53)
Male 1,901,232 (48) 2,759,416 (47) 4,263,838 (52)
Unspecifieda 14 299 156
Region
East 1,261,896 (32) 2,132,166 (36) 2,825,566 (31)
Midwest 1,605,019 (40) 2,312,937 (39) 2,697,553 (30)
South 324,678 (8) 404,490 (7) 2,151,521 (24)
West 803,290 (20) 1,008,531 (17) 1,373,790 (15)
Total 3,994,883 5,858,124 9,048,430
Overall total 5,621,520 8,139,941 12,538,475
a Unspecified numbers on gender are not included in percentages
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region-specific prevalence estimates are provided in
Tables 2 and 3.
Demographic Distribution of IBD in 2009
Age and region were significantly associated with the
prevalence of CD and UC in both the pediatric and adult
populations (Table 4). Differences in sex were significant
only for CD.
Effect of Age The prevalence of both CD and UC
increased with increasing age, although for CD the prev-
alence remained fairly stable between 30 and 50 years of
age (Figs. 1, 2).
Effect of geographic region There was significant regio-
nal variation for both children and adults with CD and UC.
For both conditions, the prevalence was lower in the South
and West, as compared with the Northeast and Midwest,
except for UC among children where only the Northeast
had a significantly higher prevalence (Table 4).
Effect of sex For children, the prevalence of CD was
lower in girls than in boys [odds ratio (OR) 0.88; 95 % CI
0.81–0.97). No significant difference in sex was observed
for UC (OR 0.93; 95 % CI 0.83–1.04). In adults, the
prevalence of CD was higher among women (OR 1.17;
95 % CI 1.14–1.20), with no differences observed in UC
(OR 1.00; 95 % CI 0.97–1.03) (Table 4).
Extrapolation to US Population
After standardizing the data from the data set on age,
gender, and region according to 2009 US census data, we
estimate that 1,171,000 Americans have IBD (565,000 CD
and 593,000 UC). Of these, 62,000 are children (38,000
CD and 23,000 UC). Thus, 5 % of all IBD cases in the
USA are of pediatric age (\20 years).
Time Trends in IBD Prevalence
Standardized prevalence estimates based on 2009 census data
for each time period are shown in Table 5. The prevalence of
both CD and UC increased slightly in both the pediatric and
adult populations between 2004–2005 and 2008–2009
(P \ 0.001 for all comparisons). Among those individuals
younger than 20 years, standardized CD prevalence esti-
mates increased from 43 to 48 per 100,000, and UC preva-
lence increased from 27 to 29 per 100,000 (Figs. 3,4). Among
those individuals 20 years of age and older, CD prevalence
increased from 214 to 236 per 100,000 and UC prevalence
increased from 235 to 248 per 100,000 (Figs. 3, 4).
Discussion
In our source population of 12,538,475 commercially
insured Americans during the period 2008–2009, the
Table 2 Prevalence of Crohn’s disease in a commercially insured US population (2008–2009)
Age group Region
Northeast South Midwest West Overall
Pediatric (age \20 years)
Prevalence per 100,000
(95 % CI)a
65.1 (60.4–70.2) 54.1 (49.2–59.5) 61.4 (56.8–66.3) 43.2 (38.0–48.9) 57.8 (55.3–60.4)
Adult (age C20 years)
Prevalence per 100,000
(95 % CI)a
247.2 (241.5–253.1) 219.2 (213.1–225.6) 264.0 (257.9–270.2) 219.3 (211.5–227.3) 241.3 (238.1–244.5)
CI Confidence interval
a Exact 95 % confidence limits were calculated using a variation on the Wilson Score confidence interval method
Table 3 Prevalence of ulcerative colitis in a commercially insured US population (2008–2009)
Age group Region








279.3 (273.2–285.6) 226.1 (219.8–232.5) 275.0 (268.8–281.3) 263.9 (255.4–272.6) 263.0 (259.7–266.4)
a Exact 95 % confidence limits were calculated using a variation on the Wilson Score confidence interval method
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prevalence of IBD among individuals aged 20 years and
older was estimated to be 241 per 100,000 for CD and 263
per 100,000 for UC. We also estimated the prevalences for
the pediatric population (\20 years of age) to be 58 per
100,000 for CD and 34 per 100,000 for UC. When
extrapolating to the US population in 2009 based on census
data, we estimated that approximately 1,171,000 Ameri-
cans have IBD (565,000 CD and 593,000 UC). Further-
more, the prevalences of both CD and UC have slightly
increased, as is to be expected for conditions without cure
and low mortality.
Our overall CD and UC prevalence estimates in 2009
were somewhat higher than most of those reported for
Table 4 Independent effects of age, gender, and region on the prevalence of inflammatory bowel disease in a commercially insured US
population (2008–2009)
Demographic characteristics CD UC
OR (95 % CI)a P value OR (95 % CI)a P value
Pediatric (age \20 years)
Female 0.88 (0.81–0.97) 0.0059 0.93 (0.83–1.04) 0.1891
Age, years (reference = 15–19 years)
\5 0.05 (0.03–0.07) \0.0001 0.08 (0.05–0.12) \0.0001
5–10 0.10 (0.08–0.12) \0.0001 0.16 (0.13–0.20) \0.0001
10–14 0.37 (0.34–0.41) \0.0001 0.43 (0.38–0.50) \0.0001
Region (reference South)
Northeast 1.19 (1.06–1.34) 0.0002 1.14 (0.97–1.33) 0.0177
Midwest 1.16 (1.03–1.31) \0.0028 0.96 (0.82–1.13) 0.2745
West 0.85 (0.72–0.99) \0.0001 0.98 (0.81–1.18) 0.5258
Adult (age C20 years)
Female 1.17 (1.14–1.20) \0.0001 1.00 (0.97–1.03) 0.9682
Age, years (reference = 60–64 years)
20–29 0.73 (0.70–0.77) \0.0001 0.45 (0.43–0.48) \0.0001
30–39 0.84 (0.80–0.88) 0.1172 0.66 (0.63–0.69) \0.0001
40–49 0.83 (0.80–0.87) 0.0648 0.71 (0.68–0.74) 0.5788
50–59 0.88 (0.84–0.92) 0.0148 0.83 (0.80–0.87) \0.0001
Region (reference = South)
Northeast 1.13 (1.10–1.17) \0.0001 1.25 (1.20–1.29) \0.0001
Midwest 1.21 (1.16–1.25) 0.0001 1.22 (1.18–1.26) \0.0001
West 1.01 (0.96–1.05) \0.0001 1.19 (1.14–1.24) \0.0653
OR Odds ratio, CD Crohn’s disease, UC ulcerative colitis
a ORs and 95 % CIs were derived from multivariate logistic regression, after controlling for each of the other variables listed
Fig. 1 Age-specific prevalence of Crohn’s disease (CD) per 100,000
persons in a commercially insured US population, 2008–2009
Fig. 2 Age-specific prevalence of ulcerative colitis (UC) per 100,000
persons in a commercially insured US population, 2008–2009
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other recent US and Canadian studies [1–3, 5, 13], which
may reflect the increasing prevalence of IBD over time
(especially CD), given that these other studies did not use
data subsequent to 2004. The higher prevalences in our
study compared to previous studies could also have resul-
ted from our exclusion of adults aged over 65 years; the
other studies included all adults 18 years and over. Our
prevalence estimates are consistent with recent data from
Olmsted County, MN which report estimates of 273 per
100,000 for UC and 222 per 100,000 for CD in 2005. As in
our study, data from Olmsted County also demonstrate
increasing IBD prevalence in recent years. The prevalence
of CD has been reported to have increased between 1991
and 2001 [5] and that of both CD and UC to have increased
between 2001 and 2005 [14].
With regards to pediatric-specific prevalence data, our
estimates are between the prevalence estimated by
Abramson et al. in northern California (12 and 20 per
100,000 for CD and UC, respectively) and by Loftus et al.
in Olmsted County, MN (115 and 107 per 100,000 for CD
and UC, respectively) [5, 6]. Our estimates are similar to
those reported in a Canadian study, where Bernstein et al.
reported pediatric-specific prevalence estimates ranging
from 31 to 71 per 100,000 for CD and 18–31 per 100,000
for UC [13].
In our study we observed increasing prevalence with age
for children and adults with CD and UC; however, the
prevalence of CD leveled off somewhat for adults over 30.
These age effects are consistent with previous studies [1–3,
6]. We also observed a higher prevalence among males
than females in pediatric CD, with the opposite occurring
in the adult population. We did not find any significant
differences in the prevalence of UC among the sexes for
both adults and children. These results are similar to those
reported in other US and Canadian studies [3, 4, 6, 13].
The major strengths of this study are the large sample
size and the geographic diversity of the sample. These
strengths allowed us to provide up-to-date estimates of the
prevalence of IBD in a US population and describe dif-
ferences by geography, age, sex, and time period. Because
claims data lack clinical details, the results of this study are
subject to some degree of diagnostic misclassification. To
reduce the effects of misclassification, we used strict case
definitions which included the need of several healthcare
contacts associated with IBD specific ICD 9 codes as well
as pharmacy claims for IBD medications. Although similar
Table 5 Standardized prevalence estimates of CD and UC colitis in a commercially insured US population (2004–2009)
Age group 2004–2005 2006–2007 2008–2009
CD UC CD UC CD UC






























CI confidence interval, CD Crohn’s disease, UC ulcerative colitis
a Exact 95 % confidence limits were calculated using a variation on the Wilson Score confidence interval method
Fig. 3 Standardized prevalence estimates of CD per 100,000 persons
in a commercially insured US population by age group, 2004–2009
Fig. 4 Standardized prevalence estimates of UC per 100,000 persons
in a commercially insured US population by age group, 2004–2009
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to administrative case definitions that have been previously
validated in the USA and Canada [1, 2, 13], the specific
case definition has not been validated in this database.
Additionally, because individuals in the USA change
health plans approximately every 2 years, we divided our
analysis into distinct 2-year intervals where the source
population for each period was the population of plan en-
rollees with continuous insurance coverage. This may have
led to an underestimation of prevalent cases with low
healthcare utilization. However, any misclassification would
likely have been stable over the time periods studied, thus
not affecting the time trend analyses. Another limitation to
this study is the lack of data on race/ethnicity, socioeco-
nomic status, or precise geographic location of the study
population; thus, we were not able to evaluate the impact of
these factors on IBD epidemiology. A final limitation is that
this study included only individuals with commercial
insurance who were younger than 65 years; thus, Medicaid
and self-insured patients were not included. As such, our
findings may not be completely generalizable to the broader
US population and may lack comparability to other studies.
In conclusion, the burden of IBD in the USA continues to
increase, owing largely to the continued steady increase in
prevalence for these chronic conditions. The results of our
study, using insurance claims data, suggest that nearly 1.2
million Americans are living with IBD. This up-to-date
epidemiological data may be used to support disease sur-
veillance and inform policy, including anticipating the need
for clinical services by this patient population, establishing
research priorities, and supporting IBD advocacy efforts.
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